Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.

Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.

Item
http://www.wikidata.org/entity/Q39332369
Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-AnalysisTrends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma.The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple MyelomaThe outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution.Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare DatabaseFollow-up of IgD-κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report.Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare.Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma.Multiple Myeloma Cells Express Key Immunoregulatory Cytokines and Modulate the Monocyte Migratory Response.Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy.Recognition of early mortality in multiple myeloma by a prediction matrix.Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study.Autologous stem cell transplantation in elderly patients with multiple myeloma: past, present, and future.Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States.
P2860

Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.

Item
http://www.wikidata.org/entity/Q39332369
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Survival of multiple myeloma p ...... the European Myeloma Network.
@en
Survival of multiple myeloma p ...... the European Myeloma Network.
@nl
type
label
Survival of multiple myeloma p ...... the European Myeloma Network.
@en
Survival of multiple myeloma p ...... the European Myeloma Network.
@nl
prefLabel
Survival of multiple myeloma p ...... the European Myeloma Network.
@en
Survival of multiple myeloma p ...... the European Myeloma Network.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Survival of multiple myeloma p ...... the European Myeloma Network.
@en
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921